CTOs on the Move


 
Afaxys mission is to deliver products and services to public health providers affordably, reliably and with an unwavering focus on customer service.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.afaxys.com
  • 455 1/2, King St
    Charleston, SC USA 29403
  • Phone: 855.888.2467

Executives

Name Title Contact Details

Similar Companies

Aspen Laser

Aspen Laser Systems is redefining pain management and recovery with our high intensity, class IV laser therapy devices. With over 30 years of experience, Aspen Laser delivers quality products and long-lasting results for your patients.

LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. We specialize in streamlining the API supply chain management throughout all development and commercial stages while providing complete technical capabilities and expert regulatory support.

Fastrack Pharmaceuticals

Fastrack Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InnovoTex

InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.